United States Patent US 8,722,657: Scope, Claim Coverage, and Patent Landscape
US 8,722,657 is a US composition-and-solid-state oriented patent. The core protected subject matter is a specific free-base anhydrous crystalline form of a single, fully specified small-molecule entity (“Compound 1”), plus (i) a pharmaceutical composition containing that crystalline form and (ii) a solvent process for preparing a pharmaceutical solution of that crystalline form.
What does US 8,722,657 claim, in plain technical scope terms?
Claim 1: Compound 1 in a defined crystalline form (free base anhydrate) with a powder XRD fingerprint
Claim 1 locks protection to three elements:
-
Molecule identity
- The claim recites “Compound 1” with a full chemical name and substituent architecture:
- A benzamide core substituted with:
- a pyrrolo[2,3-b]pyridin-5-yloxy group
- a sulfonamide group bearing:
- “3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl”
- and other moieties in the attached piperazine side chain:
- “4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)…”
- The claim also specifies the product as a free base form.
-
Solid-state identity
- “Crystalline form is Compound 1 free base anhydrate.”
-
Quantified powder X-ray diffraction (PXRD) pattern constraints
- The claim is not “any crystalline form”; it defines a powder XRD pattern (pattern A) by requiring:
- five or more peaks selected from a listed set of specific 2θ angles:
- 6.3, 7.1, 9.0, 9.5, 12.5, 14.5, 14.7, 15.9, 16.9, 18.9 degrees 2θ
- Each required peak must be within ±0.2 degrees 2θ
- Measured at about 25 °C using Cu Kα radiation (λ = 1.54178 Å)
Practical claim meaning
- In a freedom-to-operate evaluation, a product only infringes Claim 1 if:
- it contains Compound 1, and
- that Compound 1 is present as the free base anhydrate crystalline form, and
- the PXRD pattern shows at least 5 peaks from the specified list within the narrow tolerance window.
This structure creates a “fingerprint gate”: even if a competitor has the same compound, use of a different hydrate/anhydrate polymorph or a form whose PXRD set does not meet the “five or more” criterion can fall outside Claim 1.
Claim 2: Pharmaceutical composition including the crystalline form
Claim 2 depends on Claim 1 and covers:
- A pharmaceutical composition comprising:
- “the compound in said crystalline form of claim 1”
- plus “one or more pharmaceutically acceptable excipients”
Practical claim meaning
- Any dosage form (tablet, capsule, suspension, etc.) that includes the covered crystalline form meets the claim if the crystalline form requirement is met.
Claim 3: Process for preparing a pharmaceutical solution
Claim 3 depends on Claim 1 and is limited to:
- A process for preparing a pharmaceutical solution by:
- dissolving the compound in said crystalline form (from Claim 1)
- in a pharmaceutically acceptable solvent or solvent mixture
Practical claim meaning
- If a solution is prepared by dissolving the compound in a non-covered physical form, Claim 3 may not be reached. Conversely, dissolving the protected form directly can satisfy the process claim.
What is the scope boundary created by the PXRD “pattern A” requirement?
The claim’s PXRD portion is the tightest constraint and determines most of the competitive risk.
PXRD peak list and selection rule
Claim 1 uses:
-
Peak candidates (2θ degrees):
6.3, 7.1, 9.0, 9.5, 12.5, 14.5, 14.7, 15.9, 16.9, 18.9
-
Selection rule:
five or more peaks must be present from the candidate set
-
Tolerance:
±0.2 degrees 2θ around each selected peak
-
Measurement conditions:
“about 25 °C,” Cu Kα, λ = 1.54178 Å
Why “five or more peaks” matters
If a competitor’s material shows only 4 of these peaks (or the peaks are shifted beyond ±0.2 °2θ), the PXRD gate can fail, even when other peaks appear or the compound is chemically identical.
Risk assessment implication
For a product using Compound 1:
- The infringement question becomes a solid-state characterization question, not merely chemical identity.
- A viable design-around often targets:
- switching to another hydrate/polymorph
- forming a different crystallite morphology with PXRD peak positions outside the ±0.2 °2θ windows
- using an amorphous form (if the claim requires “crystalline form,” an amorphous state can be a non-infringing pathway depending on the exact evidence)
The claim language is explicit that it is “in a crystalline form… free base anhydrate” and then quantified by PXRD.
What does the claim set cover in the value chain? (drug substance vs. drug product vs. manufacturing)
| Stage |
Covered by US 8,722,657 |
Condition |
| API solid form |
Claim 1 |
Compound 1 as free base anhydrate meeting PXRD pattern A (>=5 peaks from list, ±0.2 °2θ) |
| Formulation |
Claim 2 |
Pharmaceutical composition containing that exact crystalline form plus acceptable excipients |
| Drug product manufacturing step |
Claim 3 |
Dissolving that crystalline form in an allowed pharmaceutically acceptable solvent to make a solution |
This makes the patent useful for blocking:
- supply of the protected form to formulation partners
- downstream product manufacture if the manufacturing uses the protected crystalline form
- solution preparation used for certain dosing strategies (e.g., oral solutions, parenteral solutions, etc.)
What is the most likely competitive design-around approach under this claim language?
Under the structure of Claim 1, design-around strategies concentrate on breaking at least one of the three elements: compound identity, anhydrate free base status, or the PXRD fingerprint.
Primary design-around levers
- Switch crystalline form
- Use a different polymorph or hydrate state (not “free base anhydrate”).
- Alter PXRD signature beyond tolerance
- Even if “anhydrous” and “free base” are used, crystallization conditions can change peak positions.
- Use non-crystalline form
- Convert to amorphous or a different solid state in the final dosage process.
The claim’s “pattern A” list is narrow, and the tolerance is tight (±0.2 °2θ), which makes PXRD-based evidence central.
How does this patent likely sit in the broader patent landscape for the underlying drug?
US 8,722,657 is structured as a solid-state form patent rather than a broad chemical entity patent. In practice, entity-level patents (core compound, core scaffold, or general use) typically appear as earlier, broader filings, while solid-state patents appear later to extend protection around:
- specific salt forms, polymorphs, solvates, and hydrates
- specific “formulation-relevant” solid states (e.g., improved stability, manufacturability, or dissolution)
Given Claim 1’s dependence on a specific crystalline “free base anhydrate” and PXRD pattern, the patent is a strong candidate for a late-stage life-cycle layer rather than the earliest claim of invention.
Landscape segmentation (how the market will see it)
- Earlier-layer risk: chemical entity and core pharmacology (often broader, often harder to design around).
- This-layer risk: the exact solid-state identity and fingerprint (narrower, but easier to break if competitors can identify an alternative solid form).
What does the claim structure imply for enforcement strategy?
Because Claim 1 is an API solid-state claim, enforcement can target:
- suppliers of the anhydrate free base crystalline form
- contract manufacturers producing that form for formulation
- formulation labels and product documentation showing the solid-state form used
Claim 2 expands enforcement into product composition. Claim 3 expands enforcement into manufacturing for solutions.
The enforcement leverage increases when competitors:
- use the same form at scale
- rely on the patented form’s known manufacturability/stability advantages
Key takeaways on scope and competitive positioning
- US 8,722,657 protects a single chemical entity (Compound 1) only when present as a specific “free base anhydrate” crystalline form.
- Claim 1 is governed by a PXRD fingerprint gate: at least 5 peaks chosen from 10 specified 2θ values, each within ±0.2 °2θ, at ~25 °C, Cu Kα.
- Downstream coverage exists for (i) compositions with that form and (ii) solutions prepared by dissolving that form.
- Design-around feasibility turns on solid-state control: selecting a non-covered polymorph/hydrate or generating a PXRD signature that fails the “>=5 peaks” and tolerance requirements.
Key Takeaways
- Protection is not “Compound 1 in any form.” It is Compound 1 as a free base anhydrate crystalline form meeting pattern A PXRD requirements.
- PXRD peak presence and position are the primary infringement determinants: >=5 of the listed peaks, each within ±0.2 °2θ.
- Formulation and solution processes are covered when they use the patented crystalline form.
- The patent is best understood as a solid-state life-cycle layer: the main competitive lever is using an alternative solid-state form that does not satisfy the PXRD fingerprint.
FAQs
1) Does US 8,722,657 cover all solid forms of Compound 1?
No. Claim 1 is limited to Compound 1 in the free base anhydrate crystalline form with a specific PXRD pattern A meeting the stated peak selection rule.
2) What PXRD evidence is most relevant to infringement analysis?
The material’s PXRD at about 25 °C with Cu Kα radiation, showing at least five peaks selected from the listed 2θ angles and each within ±0.2 °2θ.
3) Can a competitor avoid infringement by using a different hydrate?
If the substitute is not the free base anhydrate crystalline form (or its PXRD does not match the required pattern), it can fall outside Claim 1. Dependent coverage in Claims 2 and 3 also tracks the covered crystalline form.
4) Does the patent cover finished drug products?
Yes. Claim 2 covers pharmaceutical compositions that include the protected crystalline form plus acceptable excipients.
5) Does it cover manufacturing steps beyond dissolving a solution?
Claim 3 specifically covers a process for preparing a pharmaceutical solution by dissolving the protected crystalline form in a pharmaceutically acceptable solvent or mixture of solvents.
References
[1] US Patent 8,722,657, “Crystalline Form of Compound 1” (claims as provided).
